Ensure veterans and others with treatment-resistant mental health conditions have access to safe, evidence-based care, including continued FDA evaluation of entactogen- and psychedelic-assisted therapies with transparency, urgency, and scientific rigor.

We remain committed to ensuring that Veterans and others living with treatment-resistant mental health conditions have access to safe, evidence-based care. We respectfully urge the FDA to continue its evaluation of entactogen- and psychedelic-assisted therapies with transparency, urgency, and scientific rigor as the agency carries out its statutory responsibilities.

Correa joined members of Congress in committing to ensure access to safe, evidence-based mental health care and urging FDA to continue evaluating entactogen- and psychedelic-assisted therapies urgently and rigorously.

CORREA, BERGMAN LEAD CALL TO EXPEDITE REVIEW OF PSYCHEDELIC THERAPY
primary · press_release · model gpt-5.5

People reported in the last lookback window that former Navy SEAL Marcus Capone and VETS have helped fund treatment for nearly 1,300 ex-military personnel and are campaigning to legalize and research ibogaine further in the U.S.; the article describes ibogaine as illegal in the U.S.

Recent reporting indicates veteran demand and nonprofit-supported access continue, but federal legal/clinical access remains unresolved for ibogaine-assisted treatment.

unresolved same_term

Dad of 2 Was on Brink of Divorce and Death When Illegal Hallucinogen Saved Him. Now He's Helping Other Veterans
secondary · model gpt-5.5 · confidence 72%

AP reported that President Trump signed an order accelerating federal reviews of psychedelic drugs, including ibogaine, and that FDA would issue fast-track national priority vouchers for three psychedelics while human trials of ibogaine were set to begin in the U.S.

Federal executive action and FDA-related review acceleration support partial progress toward continued evaluation with urgency, but not broad approved access.

partial same_term

Trump signs order to speed review of psychedelics, including the controversial drug ibogaine
secondary · model gpt-5.5 · confidence 80%

The Washington Post reported that Rep. Lou Correa co-founded the Congressional Psychedelics Advancing Therapies Caucus, that lawmakers in both parties were working on legislation to boost the field, and that FDA priority vouchers went to companies studying psilocybin for depression and methylone for PTSD.

Correa is tied directly to congressional organizing around rigorous psychedelic-therapy research, and recent FDA review acceleration shows partial movement on the commitment.

partial same_term A for effort

How Republicans came to embrace psychedelic drugs
secondary · model gpt-5.5 · confidence 83%

FDA issued draft guidance to sponsors developing psychedelic drugs for medical conditions including psychiatric and substance use disorders; FDA states the term includes classic psychedelics such as psilocybin and LSD and entactogens/empathogens such as MDMA.

FDA created a public clinical-investigation framework for psychedelic and entactogen drug development, supporting transparency and scientific rigor but not patient access by itself.

partial unknown

Psychedelic Drugs: Considerations for Clinical Investigations
secondary · model gpt-5.5 · confidence 91%

FDA convened a public advisory committee meeting on new drug application 215455 for midomafetamine (MDMA) capsules submitted by Lykos Therapeutics for PTSD, with discussion of benefit-risk profile and a public comment docket.

FDA did evaluate MDMA for PTSD through a public advisory process, satisfying part of the evaluation/transparency element of the claim.

partial unknown

June 4, 2024 Meeting of the Psychopharmacologic Drugs Advisory Committee Meeting Announcement
secondary · model gpt-5.5 · confidence 90%

AP reported that an FDA advisory panel voted against MDMA for PTSD, citing flawed study data, research misconduct, safety risks, lack of follow-up data, and lack of demographic diversity.

The FDA process continued, but the leading MDMA-assisted therapy application was blocked on safety and evidence grounds, leaving access unresolved while still reflecting scientific scrutiny.

unresolved unknown

Panel rejects psychedelic drug MDMA as a PTSD treatment in possible setback for advocates
secondary · model gpt-5.5 · confidence 84%